Table 3.

Association between patient characteristics and development of moderate or severe IF/TA

VariableEffectUnadjusted OR (95% CI)IF/TA Final Model
Adjusted OR (95% CI)Pa
EBV subclinical infection12 versus 3 months4.33 (1.34 to 14.00)4.71 (1.21 to 18.38)0.025
CMV subclinical infection+ versus4.61 (1.18 to 18.07)6.76 (1.38 to 33.22)0.019
Acute rejection+ versus0.65 (0.19 to 2.25)0.74 (0.18 to 3.10)0.684
Deceased donor+ versus1.01 (0.33 to 3.08)0.75 (0.20 to 2.82)0.675
Age (years)per 1 year0.94 (0.85 to 1.03)0.89 (0.79 to 1.01)0.675
Male gender1.57 (0.53 to 4.70)1.29 (0.35 to 4.77)0.700
EBV donor statusD+ versus D4.28 (0.48 to 38.41)
EBV recipient statusR+ versus R0.84 (0.28 to 2.52)
CMV donor statusD+ versus D1.98 (0.59 to 6.70)
CMV recipient statusR+ versus R0.65 (0.17 to 2.47)
Antiviral use12 versus 3 months0.84 (0.28 to 2.52)
Caucasian+ versus1.03 (0.22 to 4.86)
Results from exploratory analysis of role of the impact of viral exposure
    log(AUC EBV)b1.2 (1.04 to 1.35)0.0109
    log(AUC CMV)b1.2 (1.06 to 1.46)0.0069
  • AUC, area under the curve.

  • aP values are from multivariate model.

  • bExploratory analysis of the role of overall viral exposure was explored in the context of the final model. ORs and P values reflect adjustment for acute rejection, deceased donor status, recipient age, and recipient gender.